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Pregnancy and postpartum viral load (VL) suppression is critical to prevent mother-to-child HIV 
transmission (MTCT) and ensure maternal health.  We measured viraemia risk before, during and after 
pregnancy in HIV-infected women. 
Methods 
Between 2010 and 2015, 1425 HIV-infected pregnant women on lifelong antiretroviral therapy (ART) for 
at least six months pre-pregnancy were enrolled in a cohort study in rural KwaZulu-Natal, South Africa.  
Odds ratios (OR) were estimated in multilevel logistic regression, with pregnancy period time varying. 
Results 
Over half of 1425 women received tenofovir-based regimens (n=791).  Median pre-pregnancy ART 
duration was 2.1 years.  Of 988 women (69.3%) with pre-pregnancy VLs; 82.0%, 6.8% and 11.2% had 
VL <50, 50-999 and ≥1000 copies/ml, respectively.  During pregnancy and at six, 12 and 24 months, VL 
was ≥1000 copies/ml in 15.2%, 15.7%, 17.8%, and 16.6% respectively; VL<50 was 76.9%, 77%, 75.5% 
and 75.8%, respectively. 
Adjusting for age, clinical and pregnancy factors, viraemia risk (VL ≥50 copies/ml) was not significantly 
associated with pregnancy [adjusted OR (aOR) 1.31; 95% confidence interval (CI) 0.90-1.92], six month 
(aOR 1.30; 95% CI 0.83-2.04), 12 month (aOR 0.96; 95% CI 0.58-1.58) and 24 month (aOR 1.40; 95% 
CI 0.89-2.22) postpartum period.  Adjusting for ART duration-pregnancy period interaction, viraemia risk 
was 1.8 and two-fold higher during pregnancy and postpartum, respectively.  
Conclusions  
While undetectable VL before pregnancy through postpartum was high, the UNAIDS goal to suppress 
90% of women was not met.  Women on preconception ART remain vulnerable to viraemia; additional 




Mother-to-Child Transmission (MTCT) is the main acquisition route of infection for children; plasma 
viral load (VL) is the main driver of  MTCT (1,2).  Potent antiretroviral therapy (ART) reduces VL 
through HIV replication interruption, decreasing MTCT risk (3–5), and improving maternal survival 
(6,7). 
Although perinatal transmission risk increases at higher maternal VLs (2) and declines at lower maternal 
VLs (8,9), MTCT may occur with low maternal viraemia (9,10) and the association between VL and 
MTCT risk is not linear (2,11,12).  In the French Perinatal Cohort, VLs 50-400 copies/ml near delivery 
increased perinatal transmission risk four-fold versus VL <50 copies/ml (9). 
With expanded ART access, HIV infected women are increasingly likely to conceive on ART (13–16).  
Maintaining viral suppression may be particularly challenging during pregnancy and postpartum with 
psychosocial, cultural and economic obstacles to adherence (17,18).  Low adherence may lead to 
virological failure, increasing MTCT and maternal drug resistance risk (19–22).  Women on 
preconception ART may also be susceptible to viraemia risk; in the UK, women on preconception ART 
and women starting pregnancy ART had a higher risk of postpartum viral rebound than non-pregnant 
controls (23).  Moreover, adherence issues in women starting ART for MTCT may differ from women 
initiating ART for their own health independent from antenatal care (24,25). 
With the expanding treatment eligibility in South Africa (16), more HIV infected women will conceive on 
ART (26).  To inform understanding of this public health programme, we explored VL and viraemia risk 
before, during and after pregnancy in HIV-infected women on ART before pregnancy. 
Methods 
Study population 
HIV-infected pregnant women attending one of 17 public sector antenatal clinics (ANC) in the Hlabisa 
HIV Treatment and Care Programme (27,28), northern KwaZulu-Natal, were eligible for inclusion. 
Women needed to be (i) on ART at least six months pre-pregnancy; (ii) not pregnant at ART initiation; 
(iii) age 15-49 years at pregnancy start; (iv) attending from 2010-2015; and (v) have at least one VL test 
one year pre-pregnancy to two years post-delivery. 
Department of Health (DoH) nurses and counsellors at ANCs and the district hospital collected routine 
pregnancy data.  Trained data capturers then entered data into a pregnancy database at the Africa Centre 
for Health and Population Studies (now Africa Health Research Institute). 
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Data capturers also routinely collected HIV and follow-up visit data from patient files, including 
medications dispensed.  Data were entered into an HIV database at the Africa Centre.  After April 2013 
(when HIV programme funding transferred to DoH), patient HIV data were collected from the Hlabisa 
pharmacy information system and the DoH HIV information system.  The National Health Laboratory 
Service (NHLS) emailed laboratory tests results weekly including CD4+ per cent/count, plasma VL, and 
HIV results; these were imported into the HIV database. Pregnancy and HIV data were linked using 
national identity numbers and other demographic characteristics (27). 
Pregnancy and postpartum definition 
Pregnancy start was defined as last menstrual period date (LMP); pregnancy end as delivery or pregnancy 
loss date.  Complete LMP data were available for 90% of pregnancies; for the remainder start and end 
dates were estimated using reported pregnancy duration based on maternal history and either first 
antenatal visit date or delivery date.  For women with missing birth outcomes, pregnancy end date was 
calculated 273 days from pregnancy start (based on median pregnancy duration).  In women with 
additional pregnancies, subsequent pregnancies were classified as repeat pregnancies (yes, no). 
“Pregnancy periods” were categorized into (i) “pre-pregnancy”, from 12 months before pregnancy to 
pregnancy start; (ii) ‘during pregnancy’ from pregnancy start to delivery; and (iii) ‘after pregnancy’ from 
the day after delivery through 24 months postpartum.  The postpartum period was further categorized as: 
first six months postpartum (postpartum, six months); 7-12 months postpartum (postpartum, 12 months); 
13-24 months postpartum (postpartum, 24 months). 
Outcome measure 
The primary outcome measure was VL ≥50 copies/ml.  The district hospital NHLS laboratory, an 
accredited laboratory under national quality control, conducted routine HIV-1 VL monitoring.  VLs were 
analysed using Nuclisens EasyQ® HIV-1 assay (Biomérieux) with a lower detection limit of 25 copies/ml 
(28).  VL testing was recommended six monthly until one year post-ART initiation; thereafter annually 
(29).  Pregnancy VL testing to determine virological suppression before delivery started in 2015 (30).  
Patients identified with virological failure (VL >1000 copies/ml after at least 12 months on a standard 
first-line regimen) were referred to clinicians for further management. 
Statistical analysis 
Differences between women with and without viraemia were analysed using a chi-square or Fisher’s 
exact test for categorical variables and Student’s t-test for continuous variables.  For the VL descriptive 
analysis, VL tests closest to pregnancy start were used if there was more than one test. 
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Participant characteristics including clinic area (peri-urban, rural), prior PMTCT (no, yes), first visit 
gestation (<20 weeks, ≥20 weeks), delivery gestation (<37 weeks, ≥37 weeks), CD4+ count in the year 
pre-pregnancy (<350, ≥350 cells/mm3), calendar delivery year (2010, 2011, 2012, 2013, 2014, 2015) and 
HIV status disclosure at ART initiation (no, yes) were included as potential confounding factors. 
Median ART duration was based on time on ART at pregnancy start.  Tenofovir (TDF)-based ART was 
phased in (27).  ART regimens were initially categorized as TDF-based, stavudine-based (d4T-based) or 
zidovudine-based (ZDV-based) (31,32).  As ZDV exposure was minimal, ZDV was combined with d4T-
based regimens (non-TDF based regimen) in multivariable models. 
In univariable analysis, the association between each variable and viraemia risk was assessed.  In model 
development, variables with p<0.2 in univariable analyses, uncorrelated (Pearson’s correlation 
coefficients, r <0.5), and biologically plausible were considered, including maternal age, ART regimen 
(TDF-based, non-TDF based) and ART regimen change from year pre-pregnancy through pregnancy end 
(yes, no).  The ART duration cutoff was based on prior evidence of an increasing trend for viraemia and 
drug resistance among women on ART over 3 years (22).  ART regimen change and age (15-24, 25-34; 
35-49) were time-varying. 
We conducted multilevel logistic regression to account for random effects of each individual over time, 
analysing viraemia risk as the outcome variable pre-pregnancy through postpartum (33).  The appropriate 
model was selected using Akaike information criterion.  A subgroup analysis was conducted for women 
with all three VLs available before, during and after pregnancy. 
Ages over 35 and under 20 have been associated with better and worse ART adherence, respectively 
(34,35).  To examine whether age modified pregnancy and viraemia risk, an interaction term for age (15–
24, 25-34, 35-49 years) and pregnancy period was included.  A separate model also explored the 
interaction between ART duration and pregnancy period; theoretically as viral reservoirs tend to diminish 
with increasing ART duration, a longer ART duration should lower viral rebound risk (36).  Statistical 
analyses were conducted using Stata 13.1. 
Ethics 
The University of KwaZulu-Natal Biomedical Research Ethics Committee provided ethics approval for 
routine HIV and pregnancy data linkage within Hlabisa (E134/06) and for this analysis (BE002/16). 
Results 
By December 2015, 30,750 pregnancies were reported.  HIV test results were known in 29,774 
pregnancies (96.8%); 41.0% were HIV-infected (12,202/29,774).  Clinical HIV data were available for 
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9479 of the12,202 pregnancies in HIV-infected women (77.7%) (Fig. 1).  Linkage was not possible for 
the remaining pregnancies due to late third trimester attendance, with national identifying data 
verification and probabilistic linkage between databases challenging.  Of the 9479 pregnancies, 21.6% 
(n=2046) were on lifelong ART pre-pregnancy; 3606 started lifelong ART during pregnancy (38.0%), 
2952 (31.1%) were on MTCT ART and 875 (9.2%) were not on pregnancy ART or prophylaxis. 
There were 404 pregnancy and 70 repeat pregnancy exclusions from the 2046 pre-pregnancy ART 
pregnancies as pregnancy laboratory data was missing, and 147 women initiated on ART less than six 
months before pregnancy were excluded (621/2046; 30.4%).  Pregnancies excluded were more likely to 
be in younger women and have a lower CD4+ count pre-pregnancy than pregnancies included in this 
analysis (p<0.01).  Thus the study population was 1425 women on ART for ≥ six months pre-pregnancy. 
Maternal characteristics (N=1425) 
Median pregnancy start age was 31 years; 23% were 15-24 years (Table 1).  Most women attended rural 
ANC clinics.  HIV status disclosure was reported in over 60% and prior PMTCT exposure in over 50% of 
women.  Only 1095 women (76.8%) had birth outcome data; of these 89.0% (n=975) had infants born at 
≥ 37 gestational weeks (Table 1). 
Median initiation CD4+ was 164 cells/mm3; pre-pregnancy CD4+ was 477 cells/mm3 (Table 1).  There 
were 203 (14.3%) women with pre-pregnancy and antenatal ART regimen changes.  Median ART 
duration was 2.1 years at pregnancy start.  Over 50% of women received TDF-based ART and under 42% 
used d4T-based regimens with either efavirenz or nevirapine; only 37 women (2.6%) used ZDV during 
pregnancy. 
Table 1 also shows pre-pregnancy group characteristics (N=988) by VL.  Women with viraemia were 
significantly older, more likely to have disclosed their HIV status, with lower pre-pregnancy CD4+ 
counts, more likely to be on ART for ≥3 years and on a d4T-based regimen pre-pregnancy than those 
non-viraemic. 
VL testing before, during and after pregnancy (N=1425) 
Overall there were 3941 VL observations in 1425 women; 16.8% (n=660) of VL tests were ≥1000, 7.9% 
(n=312) 50-999, and 75.3% (n=2969) were <50. 
Of the 988 (69.3%) women with pre-pregnancy VL, 82.0%, 6.8% and 11.2% had VL <50, 50-999 and 
≥1000, respectively (Table 2).  Of 854 (60%) women with pregnancy VLs, VL <50, 50-999 and ≥1000 
were reported in 76.9%, 7.8% and 15.2% of women, respectively. 
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There were 527 (37.0%), 437 (30.7%) and 656 (46.0%) women with VL tests through six, 12 and 24 
months postpartum (Table 2), of whom 7.2%, 6.6% and 7.6% had VL 50-999 copies/ml, respectively.  
VL was ≥1000 in 15.7%, 17.8%, and 16.6% and virological suppression was 77%, 75.5% and 75.8% at 
six, 12 and 24 months respectively. 
VL distribution in women with VL tests before, during and six months postpartum (n=150) 
There were 150 women with VL tests pre-pregnancy through six month postpartum.  VL <50 was seen in 
70.0% pre-pregnancy, 68.7% during and 71.3% after pregnancy. VL 50-999 was observed in 11.3%, 
8.7% and 9.3% in the three periods and VL was ≥1000 in 18.7% pre-, 22.7% during and 19.3% post-
pregnancy (Table 2). 
Of 45 women with unsuppressed pre-pregnancy VL, 12 (26.7%) suppressed antenally, 9 (20.0%) had VL 
50-999 copies/ml, and 24 (53.3%) had pregnancy VL ≥1000.  Within six months postpartum, 13 were 
suppressed (28.9%), 11 (24.4%) had VL 50-999 copies/ml, and 21 (46.7%) had VL ≥1000.  Of the 47 
women with pregnancy VL >50, 12 (25.5%) suppressed within six months postpartum, 10 (21.3%) had 
VL 50-999 copies/ml, and 25 (53.2%) had VL ≥1000. 
Risk factors for viraemia in women on ART for six months or longer (N=1425) 
Overall, there were 24.7% VL tests ≥50 copies/ml (972/3941).  Crude analysis showed no significant 
viraemia risk by pregnancy period.  Age >34 significantly reduced viraemia risk by 54%, but age <25 
years did not differ from the 25-34 year group.  Pre-pregnancy CD4+ count ≥350 cells/mm3 lowered 
viraemia risk [unadjusted odds ratio (OR) 0.04; 95% confidence interval (CI) 0.02-0.09] (Table 3).  Non-
TDF regimens significantly increased viraemia risk seven-fold and ART duration ≥3 years was 
marginally associated with viraemia risk.  First ANC visit ≥20 weeks increased pregnancy viraemia risk 
to 3.37 (p<0.01).  Viraemia risk was reduced in 2014 and 2015. 
In multivariable analyses adjusting for age, clinical and pregnancy factors (Table 3), pregnancy, six and 
24 month postpartum viraemia risk non-significantly increased to 1.3 to 1.4-fold, respectively.  Viraemia 
risk almost doubled compared to the univariable analysis, remaining significantly associated with age 
>34, but not age <25 years (95% CI 0.96-4.20). 
Clinical factors remained significant for viraemia, particularly CD4+ count, ART regimen and ART 
duration.  Pre-pregnancy CD4+ ≥350 cells/mm3 was protective, while non-TDF regimens significantly 
increased viraemia risk 3.3-fold.  ART duration ≥3 years and late first ANC attendance significantly 
increased viraemia risk three-fold and 2.7-fold, respectively.  There was a trend towards progressively 
reduced risk from 2012 through 2015. 
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In the multivariable model assessing whether ART duration modified viraemia risk in each pregnancy and 
postpartum period, with variables from Table 3 (Table 4), pregnancy, six and 24 month postpartum 
viremia risk significantly increased to 2.25, 1.81 and 2.82, respectively.  Viraemia risk lowered during 
pregnancy and postpartum if on ART for ≥3 years (12, 24 months).  Age <25 and >34 also significantly 
affected viraemia risk (adjusted OR 2.19 and 0.33, respectively).  Although confidence intervals were 
wide, ART duration ≥3 years remained significant. 
In the model assessing whether pregnancy start age modified the association with pregnancy period 
(Table 5), viraemia risk was 1.89 (95% CI 1.16-3.09) in pregnancy compared to pre-pregnancy, but the 
increased viraemia risk postpartum was not significant.  Although the pregnancy and 12 month interaction 
term were significant in age >34, the aOR for other covariates were not substantially altered; the age aOR 
lost statistical significance. 
In subgroup analysis of 150 women with VLs before, during and after pregnancy (Table S1), pregnancy 
(aOR 1.28; 95% CI 0.50-3.28) and postpartum (aOR 0.99; 95% CI 0.34-2.90) were not significantly 
associated with viraemia. 
Discussion 
In this rural setting where HIV prevalence is high, virological suppression pre-pregnancy through 24 
months postpartum was relatively high.  Although crude viraemia risk was not associated with pregnancy 
period, in the model including an ART duration- pregnancy period interaction term, viraemia risk was 
increased in pregnancy and postpartum. 
In our study, pre-pregnancy virological suppression reached 82%, narrowly missing the 90% UNAIDS 
goal.  In prior research including South Africa, viral suppression among pregnant or breastfeeding women 
ranged from 27 to 78% (22,37,38).  Conversely, in Malawi and Uganda, over 90% were suppressed 
(25,39).   
Consistent with increased pregnancy viraemia risk in our study, in a South African study of 541 
pregnancies in 5954 women, pregnancy after ART initiation modestly increased virological failure risk 
[aHR 1.34; 95% CI 1.02 to 1.78] (40).  Findings were based on observational data from one clinic without 
pre-initiation VL, and confounding cannot be ruled out.  Pregnancy viraemia was not observed in 1041 
women on pre-pregnancy ART from seven African countries (41) or in three other studies with smaller 
sample sizes (42–44).  Notably, these cohort studies had rigorous study procedures which may have 
positively affected ART adherence, follow-up and VL outcome.  As our and the prior South African study 
were part of ongoing HIV programmes, findings may reflect more closely a real world setting (17). 
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Postpartum viraemia risk in our study corroborates a UK study of 19 HIV clinics where 623 women on 
preconception ART had higher rebound postpartum than non-pregnant controls (<3 months: aHR 6.63; 
95% CI 3.58–12.29; 3–12 months: aHR 4.05; 95% CI 2.03–8.09) (23).  Similar results were reported in 
Tanzanian women starting ART in late pregnancy where over 10% (n=73) had postpartum VLs >400 
copies/ml between 3-24 months (45).  While differing designs, ART regimens and study populations 
complicate interpretation, a commonality between studies are postpartum issues which limit viral control 
(46). 
We showed increased pregnancy and postpartum viraemia risk only when ART duration and age were 
included as effect modifying covariates.  Longer ART duration should reduce viraemia risk as viral 
reservoirs decline over time (36).  In this study, longer ART duration independently increased the risk of 
viraemia, consistent with the higher viraemia trend around delivery among Rwandan women on ART for 
>3 years (22).  However, when ART duration was combined with viraemia risk through the pregnancy 
period, longer ART duration in pregnancy and postpartum reduced viraemia risk in our study, confirming 
diminishing VL over time and consistent with a small study in Benin where ART was started in 
pregnancy (47).  Selection bias with inclusion of women with VL tests who are more likely to be engaged 
with care, unknown confounding or measurement effect, may explain these conflicting findings.  More 
data is needed to tease out the ART duration effects on the risk of viraemia, particularly adherence 
measures during pregnancy and postpartum (48). 
Age was strongly associated with viraemia with risk decreasing in older women and increasing in 
younger women.  While the younger age association lost statistical significance in the model allowing for 
interactions, these results relating to older age match those observed in earlier studies (23,40,47).  In nine 
Southern African countries, adolescents were more likely to have imperfect adherence versus adults, and 
adolescents with virologic suppression had shorter viral rebound time versus adults (aHR 2.03; 95% CI 
1.31–3.13) (35). 
There are several reasons for compromised viral control during the pregnancy and postpartum.  
Pregnancy may affect HIV-related outcomes through physiological, immunological, and hormonal 
changes that compromise adherence, lower drug levels to sub-therapeutic and increase ART resistance 
(49–51).  Late antenatal attendance may also affect viral control, as observed in this study.  Conversely, 
frequent ANC visits may improve VL control (47).  Unexpectedly in our study, women on pre-pregnancy 
ART with monthly attendance for medication were unlikely to engage early with pregnancy services as 
staff did not formally refer between services provided at the same location by different providers from 
2010 to 2014 (29).  From 2015, pregnant women received HIV care within antenatal clinics (30); service 
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integration and guideline recommendations to monitor pregnancy VL may have contributed to the 
reduced viraemia risk trend in later years. 
Several studies have demonstrated women are vulnerable to non-adherence and healthcare disengagement 
postpartum (25,52–54), a crucial period for virological control to minimise breastfeeding transmission 
risk.  In Malawi, age <24 and poor adherence were associated with two-fold non-retention risk; patients 
on Option B+ had higher attrition than non-pregnant women initiating ART (54).  Similar results have 
been observed in South African pregnant women on ART for their own health, with attrition higher 
postpartum than antenatally (55).  Myer et al have suggested that postnatal services prioritise childcare, 
and women with chronic conditions such as HIV require additional support to manage their health (46).  
Healthcare disengagement drivers are complex and multifactorial requiring comprehensive interventions 
(46). 
MTCT risk increases almost three-fold per log10 increase in VL (56), with initial rapid declines per 
additional week of ART, plateauing around 15 weeks (5).  The window for timely intervention of high 
VLs is therefore narrow.  In South Africa, VL testing is recommended at the first antenatal visit in women 
on preconception ART (at three and six months in women initiating pregnancy ART) with results 
reviewed within two weeks (30).  In women with VL under 1000 copies, six monthly VL testing is 
recommended through pregnancy and breastfeeding; VL is repeated in one month with virologic failure.  
As pregnancy and breastfeeding is time-sensitive, even one month may be too long especially in women 
who present late for antenatal care.  Ideally, women with detectable VLs should be managed as high risk 
with follow-up within days for adherence support and repeat VL testing within weeks (57).  Moreover, 
infants should be rapidly identified as high MTCT risk and provided with extended PMTCT prophylaxis, 
appropriate HIV testing and vigilant maternal monitoring to promptly manage detectable VL during 
breastfeeding (30). 
Strengths and limitations 
Our findings come from a large pregnancy cohort of HIV-infected women in a real world setting with 
high population ART coverage (58) and is generalisable to other rural public health programmes in sub-
Saharan Africa.  While South Africa recognizes the necessity for pregnancy VL monitoring (30), few 
studies have evaluated programmatic viral control; this study offers additional insight into viraemia risk 
and identified vulnerable groups, especially younger women.  Further research is required to determine 




Subgroup analysis of women with VLs pre-pregnancy through month six postpartum suggested similar 
pregnancy and postpartum viraemia risk.  However, women without any VLs one year pre-pregnancy 
through two years postpartum were not eligible for inclusion in the study, and the VL data presented may 
represent a best case scenario for women engaged with health care where plausibly there were 
opportunities for clinical intervention.  This raises questions about the health of women who were 
excluded and consequences for their infants; missing VL data suggests poor health care engagement with 
late third trimester attendance.  The bias associated with incomplete data and attrition would suggest we 
underestimated viraemia risk.  Improved ART and antenatal service linkage, support for women who may 
become pregnant while in ART care, patient tracing and home-based visits may be necessary to improve 
health care engagement and follow-up.  Further, detection bias in this study is possible as women had 
more VL tests preconception than in pregnancy or postpartum; repeat VL testing may have been indicated 
for women already identified as high risk pre-pregnancy, which would have overestimated viraemia risk.  
Although our study VL cutoff was stringent, viraemic risk was related mainly to those with clinical 
failure with 16.8% having VL ≥1000 and 7.9% with VLs 50-999 copies/ml.  We also cannot exclude 
mortality in this group, although in this area maternal mortality is low (59).  We received VL data directly 
from the laboratory suggesting information bias related to data collection is less likely.  As data analysed 
was from a real world setting, we cannot rule out residual confounding due to inaccurate or incomplete 
covariate measurement, and were unable to adjust for baseline VL and other demographic characteristics 
such as education level. 
Conclusions 
This study supports prior studies that identified increased pregnancy and postpartum viraemia risk.  
Routine VL monitoring with sustained virologic suppression is crucial to minimise pregnancy and 
breastfeeding HIV transmission and maintain maternal health.  ART adherence is a major public health 
concern, especially in pregnant and lactating HIV-infected women on ART.  These women require 
additional support to ensure viral control, and limit drug-resistant virus and pregnancy and postpartum 
MTCT. 
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